Praveen Thaggikuppe Krishnamurthy (Praveen Krishnamurthy, Praveen T Krishnamurthy)

Scopus Author ID ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 28

Top Venues

Neurochemical research

Advanced pharmaceutical bulletin

Brain sciences

Drug development and industrial pharmacy

JSS College of Pharmacy

JSS College of Pharmacy (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

JSS College of Pharmacy Apr 20 2007

India

Professor :: Dept. of Pharmacology

Education History

JSS College of Pharmacy Apr 20 2007

India

PHD :: Dept. of Pharmacology

Publications

Deepak Vasudevan Sajini, Praveen Thaggikuppe Krishnamurthy, Amritha Chakkittukandiyil, Ravi Naik Mudavath
Correction: Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease. Neurochemical research (2024)
Deepak Vasudevan Sajini, Praveen Thaggikuppe Krishnamurthy, Amritha Chakkittukandiyil, Ravi Naik Mudavath
Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease. Neurochemical research (2024)
Deepak Vasudevan Sajini, Praveen Thaggikuppe Krishnamurthy, Amritha Chakkittukandiyil, Ravi Naik Mudavath
Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease. Neurochemical research 49 (6) (2024)
Deepak Vasudevan Sajini, Praveen Thaggikuppe Krishnamurthy, Amritha Chakkittukandiyil, Ravi Naik Mudavath
Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease. Neurochemical research 49 (6) (2024)
Ammu V V V Ravi Kiran, G Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy, Asha P Johnson, Madhuchandra Kenchegowda, Riyaz Ali M Osmani, Amr Selim Abu Lila, Afrasim Moin, Hosahalli Veerabhadrappa Gangadharappa, Syed Mohd Danish Rizvi
An Update on Emergent Nano-Therapeutic Strategies against Pediatric Brain Tumors. Brain sciences 14 (2) (2024)
Ammu V V V Ravi Kiran, G Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy, Asha P Johnson, Madhuchandra Kenchegowda, Riyaz Ali M Osmani, Amr Selim Abu Lila, Afrasim Moin, Hosahalli Veerabhadrappa Gangadharappa, Syed Mohd Danish Rizvi
An Update on Emergent Nano-Therapeutic Strategies against Pediatric Brain Tumors. Brain sciences 14 (2) (2024)
Deepak Vasudevan Sajini, Praveen Thaggikuppe Krishnamurthy, Amritha Chakkittukandiyil, Ravi Naik Mudavath
Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease. Neurochemical research (2024)
Ammu V V V Ravi Kiran, G Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy, Asha P Johnson, Madhuchandra Kenchegowda, Riyaz Ali M Osmani, Amr Selim Abu Lila, Afrasim Moin, Hosahalli Veerabhadrappa Gangadharappa, Syed Mohd Danish Rizvi
An Update on Emergent Nano-Therapeutic Strategies against Pediatric Brain Tumors. Brain sciences 14 (2) (2024)
Deepak Vasudevan Sajini, Praveen Thaggikuppe Krishnamurthy, Amritha Chakkittukandiyil, Ravi Naik Mudavath
Orientin Modulates Nrf2-ARE, PI3K/Akt, JNK-ERK1/2, and TLR4/NF-kB Pathways to Produce Neuroprotective Benefits in Parkinson's Disease. Neurochemical research (2024)
Ammu V V V Ravi Kiran, Garikapati Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy, Bhadram Kalyan Chekraverthy
Translational Challenges in Cancer Nanotherapy. Advanced pharmaceutical bulletin 14 (2) (2023)
Dhritiman Roy, Shivaramakrishnan Balasubramanian, Praveen Thaggikuppe Krishnamurthy, Piyong Sola, Emdormi Rymbai
Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential. Cellular and molecular neurobiology (2023)
Ammu V V V Ravi Kiran, Garikapati Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy, Bhadram Kalyan Chekraverthy
Translational Challenges in Cancer Nanotherapy. Advanced pharmaceutical bulletin 14 (2) (2023)
Ammu V V V Ravi Kiran, Garikapati Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy
ChatGPT in Drug Discovery Process. Advanced pharmaceutical bulletin 14 (1) (2023)
Ammu V V V Ravi Kiran, Garikapati Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy
ChatGPT in Drug Discovery Process. Advanced pharmaceutical bulletin 14 (1) (2023)
Suman Manandhar, K Sreedhara Ranganath Pai, Praveen Thaggikuppe Krishnamurthy, Ammu V V V Ravi Kiran, Garikapati Kusuma Kumari
Identification of novel TMPRSS2 inhibitors against SARS-CoV-2 infection: a structure-based virtual screening and molecular dynamics study. Structural chemistry 33 (5) (2022)
Suman Manandhar, K Sreedhara Ranganath Pai, Praveen Thaggikuppe Krishnamurthy, Ammu V V V Ravi Kiran, Garikapati Kusuma Kumari
Identification, virtual screening and molecular dynamic analysis of novel TMPRSS2 inhibitors from natural compound database as potential entry-blocking agents in SARS-CoV-2 therapy. Structural chemistry 33 (5) (2022)
Yunwei Li, Nagashree Ks, Gowramma Byran, Praveen Thaggikuppe Krishnamurthy
Identification of Selective PPAR-γ Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay. Applied biochemistry and biotechnology (2022)
Kusuma Kumari Garikapati, Ravi Kiran Ammu V V V, Praveen Thaggikuppe Krishnamurthy, Narenderan S T, Babu B, Krishnaveni Nagappan
Quantification of rosiglitazone in rat plasma and tissues via LC-MS/MS: Method development, validation, and application in pharmacokinetic and tissue distribution studies. Biomedical chromatography : BMC 36 (5) (2022)
Garikapati Kusuma Kumari, Ammu V V V Ravi Kiran, Praveen Thaggikuppe Krishnamurthy
Preliminary evaluation on the beneficial effects of pioglitazone in the treatment of endometrial cancer. Medical oncology (Northwood, London, England) 38 (6) (2021)
Sai Varshini Magham, Praveen Thaggikuppe Krishnamurthy, Neenu Shaji, Lalithkumar Mani, Shivaramakrishnan Balasubramanian
Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials. Journal of neuroscience research 99 (11) (2021)
Ammu V V V Ravi Kiran, Garikapati Kusuma Kumari, Praveen Thaggikuppe Krishnamurthy
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer. Investigational new drugs (2021)
Pavan Kumar Chintamaneni, Praveen Thaggikuppe Krishnamurthy, Sai Kiran S S Pindiprolu
Polysorbate-80 surface modified nano-stearylamine BQCA conjugate for the management of Alzheimer's disease. RSC advances 11 (10) (2021)
Piyong Sola, Praveen Thaggikuppe Krishnamurthy, Pavan Kumar Chintamaneni, Sai Kiran S S Pindiprolu, Mamta Kumari
Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson's disease management. Expert opinion on drug delivery 17 (8) (2020)
Mamta Kumari, Praveen Thaggikuppe Krishnamurthy, Sai Kiran S S Pinduprolu, Piyongsola Sola
DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment. Advanced pharmaceutical bulletin 11 (4) (2020)
Sai Kiran S S Pindiprolu, Praveen Thaggikuppe Krishnamurthy, Venkata Rao Ghanta, Pavan Kumar Chintamaneni
Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer. Nanomedicine (London, England) 15 (16) (2020)
Venkata Rao Ghanta, Nagaraju Madala, Aparna Pasula, Sai Kiran S S Pindiprolu, Kumara Swamy Battula, Praveen Thaggikuppe Krishnamurthy, Balamurali Raman
Novel dermacozine-1-carboxamides as promising anticancer agents with tubulin polymerization inhibitory activity. RSC advances 9 (32) (2019)
Mahesh Thondawada, Ashish Devidas Wadhwani, Dhanabal S Palanisamy, Hanumant Singh Rathore, Ramesh C Gupta, Pavan Kumar Chintamaneni, Malay K Samanta, Anil Dubala, Sameer Varma, Praveen Thaggikuppe Krishnamurthy, Kuppusamy Gowthamarajan
An effective treatment approach of DPP-IV inhibitor encapsulated polymeric nanoparticles conjugated with anti-CD-4 mAb for type 1 diabetes. Drug development and industrial pharmacy 44 (7) (2018)
Sai Kiran S S Pindiprolu, Pavan Kumar Chintamaneni, Praveen Thaggikuppe Krishnamurthy, Kinnera Ratna Sree Ganapathineedi
Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells. Drug development and industrial pharmacy 45 (2) (2018)

Praveen Thaggikuppe Krishnamurthy.css-eqlu8i{font-size:small;padding-left:4px;} (Praveen Krishnamurthy, Praveen T Krishnamurthy)

Publication Activity (10 Years)

Top Topics

Top Venues

Praveen Thaggikuppe Krishnamurthy (Praveen Krishnamurthy, Praveen T Krishnamurthy)